VTX-2735

N/A

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameVTX-2735
Drug Alias NameZMG-2735VTX-2735
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsInflammationCryopyrin-Associated Periodic SyndromesPericarditis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesZomagen Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZomagen Biosciences LtdVentyx Biosciences Inc
Inactive CompaniesN/A
Active IndicationsInflammationCryopyrin-Associated Periodic SyndromesPericarditis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A